SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Micrologix biotech
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Graham Dellaire who wrote (578)9/23/1999 6:45:00 AM
From: Graham Dellaire   of 792
 
Comments on Synercid.

Advantages over MBI's drugs
1. on the market Oct. 1st
2. Being distributed by a big pharma Rhone-Poulenc Rorer

Disadvantages vs. MBI's drug
1. Brutual side-effects.
2. only 52% affective vs. a limited range of bugs
3. not a new drug at all but a mix of two known drugs that act on a protein sythesis (target of many anti-bacterials... therefore nothing new here).
4. Worries about resistance developing (not a problem with MBI's drugs so far as no resistance has been seen in any experimental trials or work so far).

Any one else have any comments?

Graham
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News